Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nusinersen Phase 2 in Infantile-Onset SMA
NCT01839656Phase 2Completed
- Sponsor
- Biogen
- Start
- May 2013
- Primary completion
- Aug 2017
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 2
01
Overview
A Phase 2 trial of nusinersen in spinal muscular atrophy (SMA), sponsored by Biogen. Started May 2013; status: completed.
02
Drugs
nusinersen
03
Conditions
spinal muscular atrophy (SMA)
Beyond the preview
Go deeper on NCT01839656.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01839656.